loading
Lantheus Holdings Inc stock is traded at $74.24, with a volume of 1.33M. It is down -1.97% in the last 24 hours and up +0.86% over the past month. Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
See More
Previous Close:
$75.73
Open:
$75.48
24h Volume:
1.33M
Relative Volume:
1.38
Market Cap:
$4.80B
Revenue:
$1.54B
Net Income/Loss:
$233.56M
P/E Ratio:
22.05
EPS:
3.3669
Net Cash Flow:
$348.64M
1W Performance:
-7.72%
1M Performance:
+0.86%
6M Performance:
+39.47%
1Y Performance:
-25.34%
1-Day Range:
Value
$73.82
$75.77
1-Week Range:
Value
$73.82
$81.47
52-Week Range:
Value
$47.25
$108.91

Lantheus Holdings Inc Stock (LNTH) Company Profile

Name
Name
Lantheus Holdings Inc
Name
Phone
978 671-8001
Name
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Name
Employee
1,193
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
LNTH's Discussions on Twitter

Compare LNTH vs TAK, ZTS, HLN, TEVA, UTHR

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LNTH icon
LNTH
Lantheus Holdings Inc
74.24 4.80B 1.54B 233.56M 348.64M 3.3669
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.04 56.99B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
115.93 48.94B 9.47B 2.67B 2.28B 6.0218
HLN icon
HLN
Haleon Plc Adr
9.70 43.30B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
29.14 33.94B 17.41B 1.43B 1.00B 1.2182
UTHR icon
UTHR
United Therapeutics Corp
531.82 23.31B 3.18B 1.33B 1.04B 27.90

Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-26-26 Upgrade William Blair Mkt Perform → Outperform
Dec-12-25 Upgrade Truist Hold → Buy
Oct-08-25 Downgrade Goldman Buy → Neutral
Aug-12-25 Downgrade Truist Buy → Hold
Dec-18-24 Initiated Goldman Buy
Sep-03-24 Initiated Redburn Atlantic Buy
Jul-10-24 Reiterated JMP Securities Mkt Outperform
Dec-18-23 Downgrade William Blair Outperform → Mkt Perform
Dec-04-23 Initiated TD Cowen Outperform
Sep-29-23 Initiated William Blair Outperform
Mar-08-23 Initiated JMP Securities Mkt Outperform
Nov-30-22 Initiated SVB Leerink Outperform
Oct-13-22 Initiated Mizuho Buy
May-09-22 Initiated B. Riley Securities Buy
Apr-13-22 Initiated Truist Buy
Feb-01-21 Initiated SVB Leerink Outperform
Jun-29-20 Resumed Jefferies Buy
Aug-16-19 Upgrade CJS Securities Market Perform → Market Outperform
Nov-02-17 Upgrade Wells Fargo Market Perform → Outperform
Nov-08-16 Reiterated RBC Capital Mkts Outperform
Sep-23-16 Resumed Credit Suisse Neutral
Feb-24-16 Reiterated RBC Capital Mkts Outperform
Dec-11-15 Downgrade Credit Suisse Outperform → Neutral
Sep-30-15 Downgrade Wells Fargo Outperform → Market Perform
Jul-20-15 Initiated Credit Suisse Outperform
Jul-20-15 Initiated Jefferies Buy
Jul-20-15 Initiated RBC Capital Mkts Outperform
Jul-20-15 Initiated Robert W. Baird Outperform
Jul-20-15 Initiated Wells Fargo Outperform
View All

Lantheus Holdings Inc Stock (LNTH) Latest News

pulisher
Mar 24, 2026

William Blair, Jefferies Maintain LNTH Lantheus Holdings March 2026: Outperform Buy - Meyka

Mar 24, 2026
pulisher
Mar 24, 2026

Nuclear Medicine (Radiopharmaceuticals) Market Set for Strong Growth at 9.50% CAGR Through 2034: DelveInsight | Lantheus, GE Healthcare, Novartis, Sotera Health and Others - Barchart.com

Mar 24, 2026
pulisher
Mar 24, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Mar 24, 2026
pulisher
Mar 23, 2026

CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH - MarketBeat

Mar 23, 2026
pulisher
Mar 22, 2026

Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 22, 2026
pulisher
Mar 22, 2026

Lantheus to sell SPECT Business to SHINE Technologies - MSN

Mar 22, 2026
pulisher
Mar 21, 2026

LNTH Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges LNTH Investors with Losses to Contact the Firm - The National Law Review

Mar 21, 2026
pulisher
Mar 21, 2026

Class Action Announcement for Lantheus Holdings, Inc. Investors - The National Law Review

Mar 21, 2026
pulisher
Mar 20, 2026

Form DEF 14A LANTHEUS HOLDINGS For: 20 March - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

Lantheus Holdings, Inc. ($LNTH) Former CEO 2025 Pay Revealed - Quiver Quantitative

Mar 20, 2026
pulisher
Mar 20, 2026

[ARS] Lantheus Holdings, Inc. SEC Filing - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Lantheus (NASDAQ: LNTH) 2026 proxy outlines board elections, pay and equity plan - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Lantheus says FDA extended review period for radioactive diagnostic kit - MSN

Mar 20, 2026
pulisher
Mar 19, 2026

How Lantheus Holdings Inc. (LNTH) Affects Rotational Strategy Timing - Stock Traders Daily

Mar 19, 2026
pulisher
Mar 19, 2026

Lantheus Holdings Inc (LNTH) Trading Down 3.37% on Mar 19 - GuruFocus

Mar 19, 2026
pulisher
Mar 19, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Connect - ACCESS Newswire

Mar 19, 2026
pulisher
Mar 19, 2026

Aug Weekly: Will Lantheus Holdings Inc outperform the market in YEAR2026 Key Highlights & Scalable Portfolio Growth Methods - baoquankhu1.vn

Mar 19, 2026
pulisher
Mar 18, 2026

Why Lantheus Holdings Stock Popped by Almost 12% Last Month - AOL.com

Mar 18, 2026
pulisher
Mar 18, 2026

Lantheus price target raised to $82 from $80 at Truist - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Lantheus Holdings Q4 2025 earnings preview - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Citizens reiterates Lantheus stock rating after FDA extends review By Investing.com - Investing.com Canada

Mar 18, 2026
pulisher
Mar 18, 2026

FDA extends review of Lantheus’ neuroendocrine tumor drug By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 18, 2026

Lantheus Holdings Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Lantheus says FDA pushed deadline for reviewing its tumor diagnostic kit application - MSN

Mar 18, 2026
pulisher
Mar 17, 2026

Lantheus Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Mar 17, 2026
pulisher
Mar 17, 2026

Lantheus stock holds Outperform at William Blair after FDA delay By Investing.com - Investing.com India

Mar 17, 2026
pulisher
Mar 17, 2026

Lantheus stock holds Outperform at William Blair after FDA delay - Investing.com

Mar 17, 2026
pulisher
Mar 17, 2026

Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application - Asianet Newsable

Mar 17, 2026
pulisher
Mar 17, 2026

Lantheus (LNTH) Drug Application Review Extended by FDA - GuruFocus

Mar 17, 2026
pulisher
Mar 17, 2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

Jefferies Maintains Buy on Lantheus Holdings (LNTH) Mar 17 2026 - Meyka

Mar 17, 2026
pulisher
Mar 17, 2026

US FDA extends review of Lantheus' diagnostic imaging kit by three months - Yahoo Finance

Mar 17, 2026
pulisher
Mar 17, 2026

FDA extends review of Lantheus’ neuroendocrine tumor drug - Investing.com

Mar 17, 2026
pulisher
Mar 17, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Mar 17, 2026
pulisher
Mar 17, 2026

Jefferies raises Lantheus stock price target on PSMA PET outlook By Investing.com - Investing.com Canada

Mar 17, 2026
pulisher
Mar 17, 2026

Lantheus Holdings Inc Stock (ISIN: US5156731020) Faces Pressure as Farallon Sells 3.245 Million Shar - AD HOC NEWS

Mar 17, 2026
pulisher
Mar 17, 2026

US FDA extends review of Lantheus’ diagnostic imaging kit by three months - 1470 & 100.3 WMBD

Mar 17, 2026
pulisher
Mar 16, 2026

Farallon Capital Management LLC Sells 3,245,000 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation | NDAQ:LNTH | Press Release - Stockhouse

Mar 15, 2026
pulisher
Mar 15, 2026

Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

How does Lantheus Holdings Inc compare to its peersLayoff News & Community Consensus Trade Alerts - baoquankhu1.vn

Mar 14, 2026
pulisher
Mar 14, 2026

FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging - Investing.com Nigeria

Mar 14, 2026
pulisher
Mar 14, 2026

Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat

Mar 14, 2026
pulisher
Mar 13, 2026

Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade - Oncodaily

Mar 13, 2026
pulisher
Mar 13, 2026

Lantheus Holdings (LNTH) Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA ApprovalsHas The Bull Case Changed? - simplywall.st

Mar 13, 2026
pulisher
Mar 12, 2026

Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion - Yahoo Finance

Mar 12, 2026
pulisher
Mar 12, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect - ACCESS Newswire

Mar 12, 2026
pulisher
Mar 12, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Mar 12, 2026
pulisher
Mar 12, 2026

Lantheus Stock Analysis: 57% Gain Amid Revenue and Margin ConcernsNews and Statistics - IndexBox

Mar 12, 2026
pulisher
Mar 11, 2026

Imaging & Diagnostics Stocks Decline After Q4 2025 EarningsNews and Statistics - IndexBox

Mar 11, 2026

Lantheus Holdings Inc Stock (LNTH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
RDY RDY
$13.45
price down icon 1.75%
RGC RGC
$24.43
price down icon 3.13%
$24.90
price up icon 1.88%
$127.86
price up icon 0.64%
$13.36
price up icon 0.53%
$531.82
price up icon 2.03%
Cap:     |  Volume (24h):